Zivo Bioscience Inc (ZIVO)
OTHER OTC:ZIVO
Want to see ZIVO full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Revenue Growth
The significant revenue growth trajectory indicates strong demand for Zivo's algal bioactive compounds, supporting long-term market potential and business expansion.
Negative Factors
Financial Instability
Negative equity and insolvency highlight severe financial instability, threatening Zivo's operational continuity and necessitating immediate restructuring for long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The significant revenue growth trajectory indicates strong demand for Zivo's algal bioactive compounds, supporting long-term market potential and business expansion.
Read all positive factors
Zivo Bioscience (ZIVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.86M
Dividend YieldN/A
Average Volume (3M)586.00
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth-24.29%
EPS Growth40.32%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.59
Shares Outstanding3,888,595
10 Day Avg. Volume232
30 Day Avg. Volume586
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-8.87
Price to Sales (P/S)279.23
P/FCF Ratio-10.11
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue148.54
Enterprise Value/Gross Profit450.90
Enterprise Value/Ebitda-1.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$1.19M
Zivo Bioscience Business Overview & Revenue Model
Company Description
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The comp...
How the Company Makes Money
Zivo Bioscience makes money by developing and licensing its proprietary algal bioactive compounds to companies in the nutrition, wellness, and animal health industries. The company's revenue streams largely consist of licensing fees, royalties, an...
Zivo Bioscience Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 119.03K | 157.22K | 27.65K | 0.00 | 0.00 |
| Gross Profit | 39.93K | 48.95K | 11.61K | 0.00 | 0.00 |
| EBITDA | -9.84M | -13.36M | -7.26M | -8.73M | -9.05M |
| Net Income | -9.89M | -13.38M | -7.78M | -8.75M | -9.40M |
Balance Sheet | |||||
| Total Assets | 663.60K | 1.64M | 555.72K | 2.12M | 8.99M |
| Cash, Cash Equivalents and Short-Term Investments | 67.06K | 1.54M | 274.38K | 1.80M | 8.90M |
| Total Debt | 637.20K | 254.36K | 346.34K | 445.18K | 255.18K |
| Total Liabilities | 4.41M | 2.16M | 2.76M | 2.13M | 2.95M |
| Stockholders Equity | -3.75M | -514.90K | -2.21M | -10.62K | 6.04M |
Cash Flow | |||||
| Free Cash Flow | -3.29M | -4.31M | -5.80M | -7.10M | -6.80M |
| Operating Cash Flow | -3.29M | -4.31M | -5.80M | -7.10M | -6.80M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.81M | 5.58M | 4.28M | -628.60K | 15.57M |
Zivo Bioscience Technical Analysis
Negative
2.10
Price Trends
3.61
Negative
6.47
Negative
9.41
Negative
Market Momentum
<0.01
Positive
38.31
Neutral
29.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIVO, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 3.89, below the 50-day MA of 3.61, and below the 200-day MA of 9.41, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 38.31 is Neutral, neither overbought nor oversold. The STOCH value of 29.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZIVO.
Zivo Bioscience Risk Analysis
Zivo Bioscience disclosed 26 risk factors in its most recent earnings report. Zivo Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zivo Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $11.86M | -1.46 | 426.45% | ― | -24.29% | 40.32% | |
50 Neutral | $39.29M | -2.70 | -138.61% | ― | 520.42% | 16.12% | |
49 Neutral | $384.16M | -1.71 | -53.23% | ― | -100.00% | -290.26% | |
44 Neutral | $26.52M | -2.93 | 9999.00% | ― | ― | ― | |
42 Neutral | $19.83M | -0.28 | -4086.31% | ― | ― | -73.57% | |
41 Neutral | $13.79M | -0.17 | -191.12% | ― | ― | 38.53% |
* Healthcare Sector Average
ZIVO
Zivo Bioscience
3.05
-14.16
-82.28%
JSPR
Jasper Therapeutics
0.49
-5.45
-91.72%
IPSC
Century Therapeutics
2.13
1.50
240.26%
RNXT
RenovoRx
0.87
-0.50
-36.35%
NRSN
Neurosense Therapeutics Ltd.
0.75
-1.15
-60.53%
MDCX
Medicus Pharma Ltd
0.35
-2.53
-87.85%
Zivo Bioscience Corporate Events
Executive/Board Changes
Zivo Bioscience CFO Resigns, Interim Successor Appointed
Negative
Dec 23, 2025
On December 19, 2025, Zivo Bioscience’s Chief Financial Officer, Keith R. Marchiando, resigned effective immediately and agreed to end his employment with the company on December 31, 2025, under a separation agreement that provides him with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―